<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813914</url>
  </required_header>
  <id_info>
    <org_study_id>Sineos-3</org_study_id>
    <nct_id>NCT03813914</nct_id>
  </id_info>
  <brief_title>A New Supplement for the &quot;Metabolic Syndrome&quot;</brief_title>
  <official_title>Corosolic Acid and Cinnamon for the Treatment of the &quot;Metabolic Syndrome&quot; in Menopausal Transition Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of a combination of glycirrhizic acid, Cinnamomun Zeylanicum
      and corosolic acid for the treatment of metabolic syndrome. Participants receive the
      supplement or a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The supplement is composed by of a combination of glycirrhizic acid, Cinnamomun Zeylanicum
      and corosolic acid. They act in different way reducing insulin resistance, which is the main
      cause of metabolic syndrome. It was a randomized, controlled study involving 60 women with
      the metabolic syndrome following the criteria proposed by ATP III in 2015. Main outcomes were
      the improvement of the parameters that characterizes the metabolic syndrome, such as glucose
      and insulin levels, triglycerides, HDL-cholesterol and blood pressure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glycemia</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of glycemia (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in HDL-cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Increase of HDL-C (mg/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in HOMA-IR</measure>
    <time_frame>3 months</time_frame>
    <description>measured as the ratio between glycaemia (mg/dl) and insulin (UI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in total-cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>reduction of cholesterol (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in triglycerides</measure>
    <time_frame>3 months</time_frame>
    <description>reduction in triglycerides (mg/dl)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Sineos</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2 pills/day for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sineos</intervention_name>
    <description>glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_label>Sineos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Postmenopausal women affected by Metabolic Syndrome, diagnosed by ATP
        2015 criteria.

        -

        Exclusion Criteria: treatment with steroids or with hypoglycemic or anti-cholesterol drugs

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>January 21, 2019</last_update_submitted>
  <last_update_submitted_qc>January 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Rosario D'anna</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical professor</investigator_title>
  </responsible_party>
  <keyword>insulin resistance, blood pressure,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

